Circulating miRNA-451a and miRNA-328-3p as Potential Markers of Coronary Artery Aneurysmal Disease.
Sylwia IwańczykTomasz P LehmannArtur CieślewiczKatarzyna MaleszaPatrycja WoźniakAgnieszka HertelGrzegorz KrupkaPawel Piotr JagodzinskiMarek GrygierMaciej LesiakAleksander AraszkiewiczPublished in: International journal of molecular sciences (2023)
MicroRNAs (miRNAs) are currently investigated as crucial regulatory factors which may serve as a potential therapeutic target. Reports on the role of miRNA in patients with coronary artery aneurysmal disease (CAAD) are limited. The present analysis aims to confirm the differences in the expression of previously preselected miRNAs in larger study groups and evaluate their usefulness as potential markers of CAAD. The study cohort included 35 consecutive patients with CAAD (Group 1), and two groups of 35 patients matched Group 1 regarding sex and age from the overall cohort of 250 patients (Group 2 and Group 3). Group 2 included patients with angiographically documented coronary artery disease (CAD), while Group 3 enrolled patients with normal coronary arteries (NCA) assessed during coronary angiography. We applied the RT-qPCR method using the custom plates for the RT-qPCR array. We confirmed that the level of five preselected circulating miRNAs was different in patients with CAAD compared to Group 2 and Group 3. We found that miR-451a and miR-328 significantly improved the CAAD prediction. In conclusion, miR-451a is a significant marker of CAAD compared to patients with CAD. In turn, miR-328-3p is a significant marker of CAAD compared to patients with NCA.
Keyphrases
- coronary artery
- coronary artery disease
- end stage renal disease
- cell proliferation
- long non coding rna
- chronic kidney disease
- pulmonary artery
- newly diagnosed
- emergency department
- type diabetes
- peritoneal dialysis
- atrial fibrillation
- cardiovascular events
- human health
- fluorescent probe
- living cells
- coronary artery bypass grafting
- high density
- transcription factor
- transcatheter aortic valve replacement
- single molecule
- blood flow
- high throughput